DRTS
ANALYST COVERAGE5 analysts
BUY
+4.9%upside to target
L $8.00
Med $11.50consensus
H $15.00
Buy
480%
Hold
120%
4 Buy (80%)1 Hold (20%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$964.59M
Revenue TTM
Net Income TTM
Free Cash Flow-$32.76M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-73.2%
Return on Assets-52.3%
Debt / Equity0.21
Current Ratio7.79
EPS TTM$-0.63
PRICE
Prev Close
11.18
Open
11.03
Day Range10.77 – 11.36
10.77
11.36
52W Range2.81 – 11.62
2.81
11.62
93% of range
VOLUME & SIZE
Avg Volume
494.5K
FUNDAMENTALS
P/E Ratio
-16.4x
Not profitable
EPS (TTM)
Div Yield
No dividend
TECHNICAL
RSI (14)
68
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 116 days
Sep 15

DRTS News

About

alpha tau medical (http://www.alphataumedical.com/) focuses on research, development and commercialization of alpha dart (diffusing alpha-emitters radiation therapy) for the treatment of solid cancer tumors. alpha dart technology, initially developed at tel aviv university, was shown to be effective and safe for treating different types of cancer in multiple animal studies. the company is running its first clinical trial in several sites in the eu. breakthrough technology for cancer treatment the alpha dart breakthrough technology utilizes alpha radiation to treat cancer and enables highly potent and conformal radiotherapy. alpha dart treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha emitting atoms into the tumor.

Industry
Surgical and Medical Instrument Manufacturing
Yona KeisariChief Scientific Officer & Member of Scientific Advisory board
Robert DenChief Medical Officer & Member of Scientific Advisory Board
Amnon GatChief Operations Officer
Raphi LevyChief Financial Officer
Ronen SegalChief Technology Officer
Uzi SoferChief Executive Officer & Chairman
Rebecca BeckerVice President of legal
Yael ZeigerCorporate Controller